Stereotactic radiosurgery (SRS) and immune checkpoint inhibitors (ICI) are increasingly used to treat brain metastases, however there is a paucity of prospective data on the effectiveness of these treatments in terms of cancer control.
Data from patients treated with SRS for non-small cell lung cancer (NSCLC) and melanoma brain metastases at a single facility from May 2008 to January 2017 were retrospectively examined. The impact of concurrent ICI within 30, 60, or 90 days of ICI administration on local control and remote in-brain control is examined using a parametric proportional hazard model. The regression model takes into account other patient and lesion characteristics as covariates and makes adjustments.
